文献速递脊柱关节炎

古塞奇尤单抗对生物制剂初治与肿瘤坏死因子抑制剂应答不佳的活动性银屑病关节炎患者白介素-23信号传导的调节作用

Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2024-03-04

研究比较了古塞奇尤单抗治疗活动性银屑病关节炎中生物制剂初治(n=251)与肿瘤坏死因子抑制剂应答不佳(TNFi-IR,n=93)患者的免疫学差异及与临床应答的关联。TNFi-IR组基线IL-22、TNFα和β防御素-2水平显著高于生物制剂初治组。古塞奇尤单抗在两组均显著降低IL-17A、IL-17F、IL-22等生物标志物水平,临床应答者基线多种生物标志物水平显著高于无应答者。

要点

  • TNFi-IR患者基线IL-22、TNFα和BD-2水平显著高于生物制剂初治患者。
  • 古塞奇尤单抗治疗24周在两组均显著降低IL-17A、IL-17F、IL-22、SAA、CRP、IL-6和BD-2水平。
  • 临床应答者基线IL-17A、IL-17F、BD-2、IL-22水平显著高于无应答者。

核心结论

  • 古塞奇尤单抗调节IL-23信号传导,在生物制剂初治和TNFi-IR的银屑病关节炎患者中提供一致的药效学效应。
  • TNFi-IR患者基线IL-22、TNFα和BD-2水平显著升高,且基线IL-22、IL-17A和BD-2水平与古塞奇尤单抗皮肤应答相关,提示TNFi-IR患者IL-23/Th17信号传导失调更严重。

研究设计与样本

  • pooled DISCOVER-1/DISCOVER-2/COSMOS数据集的血清生物标志物分析,比较生物制剂初治(n=251)与TNFi-IR(n=93)亚组。
  • 古塞奇尤单抗100 mg每8周给药,比较基线和治疗后生物标志物水平。

主要发现

  • 基线IL-22、TNFα和BD-2水平在生物制剂初治组显著低于TNFi-IR组。
  • 古塞奇尤单抗治疗24周,生物制剂初治组和TNFi-IR组的IL-17A、IL-17F、IL-22、血清淀粉样蛋白A、C反应蛋白、IL-6和BD-2水平较基线显著降低(≥1.4倍差异,名义P < 0.05)。
  • 生物制剂初治组PASI 90应答者基线IL-17A、IL-17F、BD-2水平显著高于无应答者(名义P < 0.05)。
  • TNFi-IR组IGA 0/1应答者基线IL-17A、BD-2水平显著高于无应答者,PASI 90应答者基线IL-22、BD-2水平显著高于无应答者(名义P < 0.05)。
  • TNFi-IR组ACR20应答者基线生物标志物水平呈升高趋势。

关键数值与推荐

  • 临床应答定义:PASI 75/90(银屑病面积和严重程度指数改善≥75%/90%)、IGA银屑病评分0/1且改善≥2分、ACR20(美国风湿病学会标准改善≥20%)。
  • 生物标志物显著降低定义为较基线≥1.4倍差异且名义P < 0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assessed and compared immunologic differences and associations with clinical response to guselkumab, a fully human interleukin (IL)-23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) who were biologic-naive or had inadequate response to tumor necrosis factor inhibitors (TNFi-IR). METHODS: Serum biomarker levels at baseline and after treatment with guselkumab 100 mg every 8 weeks were compared between biologic-naive (n = 251) and TNFi-IR (n = 93) subgroups identified in the pooled DISCOVER-1/DISCOVER-2/COSMOS data set. Baseline biomarker levels determined by achievement of week 24 clinical responses (≥75%/90% improvement in Psoriasis Area and Severity Index [PASI 75/90], Investigator's Global Assessment [IGA] of psoriasis score 0/1 and ≥2-point improvement], ≥20% improvement in American College of Rheumatology criteria [ACR20]) were compared between prior treatment subgroups. RESULTS: Baseline IL-22, TNFα, and beta defensin-2 (BD-2) levels were significantly lower in biologic-naive than in TNFi-IR participants. With guselkumab, week 24 IL-17A, IL-17F, IL-22, serum amyloid A, C-reactive protein, IL-6, and BD-2 levels were significantly reduced from baseline in biologic-naive and TNFi-IR participants (≥1.4-fold difference, nominal P < 0.05). Clinical responders to guselkumab exhibited significantly higher baseline levels of several biomarkers than nonresponders (IL-17A, IL-17F, BD-2 in biologic-naive PASI 90 responders; IL-17A, BD-2 in TNFi-IR IGA 0/1 responders; IL-22, BD-2 in TNFi-IR PASI 90 responders [nominal P < 0.05]) and trended higher in TNFi-IR ACR20 responders. CONCLUSION: Guselkumab modulates IL-23 signaling and provides consistent pharmacodynamic effects in both biologic-naive and TNFi-IR PsA patients. Significantly elevated baseline IL-22, TNFα, and BD-2 levels and associations between baseline IL-22, IL-17A, and BD-2 levels and skin responses to guselkumab suggest greater dysregulation of IL-23/Th17 signaling in patients with TNFi-IR.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Siebert S, Coates LC, Schett G, et al. Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis Rheumatol. 2024. PMID: 38253404. doi:10.1002/art.42803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。